Moderna and Merck Shares Drop After Personalized Melanoma Vaccine Data Leak
Moderna and Merck shares fell sharply after detailed data from a late-stage trial of their personalized melanoma vaccine, intismeran, leaked. The vaccine, combined with Merck's Keytruda, reduced the risk of cancer recurrence by 42% and distant metastasis by 38%. While the results marked a significant scientific advance as the first positive mRNA-based cancer therapy trial, they fell short of investors' high expectations, prompting a sell-off that erased billions from Moderna's market value.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (48/100). Lens Score 44/100.
Outlets measured: moneycontrol, economictimes. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (45–52/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
economictimes broke this story on 22 Oct, 08:15 pm. Other outlets followed.